close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

17.43 +3.40 (+24.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Top 2 Health Care Stocks That May Collapse This Quarter
 
Via Benzinga
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month
Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the... 
Via Benzinga
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Have Investors Grinning Soon
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean... 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Announces Leadership Changes
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today